Competitive pressure and market share loss
The company competes against larger device makers with more resources, and customers evaluate technology, outcomes, ease of use, and price.
- Scope
- All product lines, especially Med Device
- Materiality
- high
AngioDynamics, Inc
AngioDynamics is a U.S.-based medical technology company focused on minimally invasive devices used in cardiovascular disease and cancer care. The company designs, manufactures, and sells products for vascular access, peripheral vascular disease treatment, thrombus management, and oncology/surgical procedures. Its business has been reshaped by a series of divestitures and product-line exits, leaving a stronger emphasis on higher-growth Med Tech offerings such as Auryon, NanoKnife, and mechanical thrombectomy platforms. AngioDynamics sells primarily to hospitals and specialist physicians, using a direct sales force in the United States and distributors internationally. The company is headquartered in Latham, New York, with manufacturing primarily in Queensbury, New York, and is listed on Nasdaq under the ticker ANGO.
−5,3 %
54,6 %
−11,5 %
+9,5 %
2.19
1.49
| % | |
|---|---|
| Med Tech | 48% Higher-growth technologies for peripheral vascular disease, thrombus management, and oncology procedures, including Auryon, NanoKnife, and thrombectomy systems. |
| Med Device | 52% Core vascular access, venous, and other procedural devices sold to hospitals and clinicians, including legacy and disposable product lines. |
AngioDynamics sells to healthcare providers that perform image-guided, minimally invasive procedures, especially in...
- Hospitals and health systemsprimary
Buy AngioDynamics devices for inpatient and outpatient procedures where minimally invasive vascular and oncology tools are used repeatedly across departments.
- Interventional specialistsprimary
Interventional radiologists, cardiologists, vascular surgeons, and oncologists buy specific platforms such as Auryon, NanoKnife, and thrombectomy systems because they affect procedural performance and outcomes.
- Critical care and procedural nursing teamssecondary
Use vascular access and support products in routine care pathways where ease of use and reliability matter.
- International distributorssecondary
Purchase and resell products outside the U.S., helping the company reach markets where direct commercial infrastructure is less efficient.
AngioDynamics is headquartered in Latham, New York, and manufactures primarily in Queensbury, New York...
- •Headquartered in Latham, New York
- •Primary manufacturing in Queensbury, New York
- •U.S. sales are mainly direct-to-customer
- •International sales rely heavily on distributors
- •Most recent quarter: U.S. revenue far exceeded international revenue
- •Geographic expansion is part of the growth strategy
AngioDynamics is repositioning the business toward its Med Tech portfolio, which management describes as the main...
01
Grow Auryon, thrombectomy, and NanoKnifemedium-term
These platforms are positioned as the company’s main access points to larger and faster-growing markets.
02
Restructure manufacturing footprintshort-term
Moving most production to outsourced manufacturing is intended to lower cost and improve gross margin profile.
03
Expand clinical and regulatory supportmedium-term
Medical device adoption depends on evidence generation, physician familiarity, and regulatory clearances across jurisdictions.
AngioDynamics faces intense competition in a medical device market where larger rivals often have greater resources,...
Reimbursement and pricing pressure
Managed care, provider consolidation, and value-based purchasing can compress pricing and reduce adoption of premium devices.
- Scope
- U.S. hospital and physician customers
- Materiality
- high
Regulatory and clinical development risk
Growth depends on FDA clearances, foreign approvals, and successful clinical trials for new or expanded indications.
- Scope
- Auryon, NanoKnife, thrombectomy platforms
- Materiality
- high
Supply chain and manufacturing disruption
Inflation, raw material availability, labor shortages, shipping costs, and the shift to outsourced manufacturing can affect delivery and margins.
- Scope
- Queensbury operations and third-party manufacturers
- Materiality
- high
Cybersecurity and data integrity breaches
A breach could disrupt operations, expose IP, create legal liability, and damage customer relationships.
- Scope
- Company systems, distributors, and supply chain partners
- Materiality
- medium
Revenue recognition on product sales
Can affect quarterly comparability and reported growth rates
Goodwill and intangible asset impairment
Can create material non-cash charges
Contingent consideration fair value
Can move other income/expense and earnings
Restructuring and outsourcing transition accruals
Affects operating expenses, margins, and cash flow
: 11/08/2026